Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Redafamdastat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Redafamdastat: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
S1B-408 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
S1B-408: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Tasadenoturev Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Tasadenoturev: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
E-6201 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
E-6201: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Bashu Granules Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Bashu Granules: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Foslip Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Foslip: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Adavosertib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Adavosertib: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Donepezil/Solifenacin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Donepezil/Solifenacin: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Teruravone Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Teruravone: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Etodolac/Propranolol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Etodolac/Propranolol: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
LM-103 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
LM-103: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Cisplatin Liposomal(Eleison Pharmaceuticals) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Cisplatin Liposomal(Eleison Pharmaceuticals): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market pos